RecruitingPhase 1/2

The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients

China47 participantsStarted 2025-12-10

Plain-language summary

This is an exploratory, multicenter, single-arm study designed to evaluate the efficacy of perioperative Vonoprazan Fumarate in reducing the incidence of Delayed Graft Function (DGF) in deceased-donor kidney transplant recipients. DGF is a common early complication that significantly impacts graft function and long-term transplant survival. This study aims to explore how Vonoprazan Fumarate, a potassium-competitive acid blocker (P-CAB), can potentially improve macrophage phagocytic function, reduce kidney inflammation, and enhance early kidney function recovery. Patients aged 18 years and older who are undergoing first-time deceased-donor kidney transplantation will be enrolled. Vonoprazan Fumarate will be administered daily starting on the day of transplantation and continuing for seven days post-surgery. The primary endpoint is DGF incidence, while secondary endpoints include kidney function recovery, serum creatinine reduction, estimated glomerular filtration rate, and safety assessments. Adverse events will be monitored, and the study will also explore potential biomarkers for inflammation and graft function. The study is expected to provide insights into a potential new therapeutic strategy to reduce DGF and improve early kidney transplant outcomes, potentially benefiting future kidney transplant patients by offering a safer and more effective perioperative treatment option.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years at time of transplantation. * Undergoing first-time deceased-donor kidney transplantation. * No administration of proton-competitive acid blockers (P-CABs) in the 1 month prior to transplantation. * Consent to receive the standard immunosuppressive therapy post-transplantation. * Ability and willingness to provide informed consent and comply with study procedures and follow-up. * Complete baseline clinical data available. Exclusion Criteria: * Receiving a living-donor kidney transplant or multi-organ transplantation. * Previous history of any solid organ or cellular transplantation (with the exception of corneal transplants). * Intraoperative occurrence of hyperacute rejection or confirmed graft non-function (e.g., renal artery thrombosis). * Presence of high risk for primary graft non-function (e.g., severe injury to the transplant renal artery). * Severe postoperative intestinal obstruction requiring prolonged fasting or inability to take oral medication in perioperative period. * Known history of hypersensitivity to vonoprazan fumarate or any of its excipients. * Subjects with severe hepatic impairment (Child-Pugh Class C). * Concomitant use of strong CYP3A4 inhibitors (e.g., ritonavir, clarithromycin). * Current therapy with atazanavir or rilpivirine. * Any other condition deemed by the investigator to be inappropriate for study participation (e.g., uncontrolled active infection, severe peptic ulcer, pregnancy or lactation).

What they're measuring

Incidence of Delayed Graft Function (DGF)

Timeframe: Within the first 7 days post-transplant

Trial details

NCT IDNCT07275632

SponsorFirst Affiliated Hospital of Chongqing Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-10-31

Contact for this trial

Weiyang He, MD

+86 023-89012012 weiyang361@163.com